Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products with applications throughout the diagnostics and life sciences industries. The company has a range of instruments using its xMAP technology: its LUMINEX 100/200 systems offer 100-plex testing; its FLEXMAP 3D system is its high-throughput, 500-plex testing system; and its MAGPIX system provides 50-plex testing. The company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. As of December 31, 2015, the company had 73 strategic partners, 48 of which have developed reagent-based products utilizing its technology. Luminex and these partners have sold approximately 12,684 xMAP-based instruments in laboratories worldwide as of December 31, 2015. The company’s remaining partners are in various stages of development and commercialization of products incorporating its technology. The company’s assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Its assay products are focused on three segments of the molecular diagnostic testing market, such as human genetics, personalized medicine and infectious disease. In addition to the sales to this installed based, the company has received U.S. Food and Drug Administration (FDA) clearance for its ARIES system. The ARIES system is a sample to answer clinical test system that automates and integrates extraction of nucleic acid from a clinical sample, performs real-time polymerase chain reaction (PCR), and detects multiple signals generated by target specific probes. The ARIES system is used with specific assays to measure multiple analytes indicative of infectious disease. The ARIES system uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing both STAT and Batch testing. The ARIES system can run both in vitro diagnostics (IVD) and MultiCode analyte specific reagents simultaneously with a common Universal Assay Protocol. The ARIES system was commercially launched in 2015. The company also received FDA clearance for the ARIES HSV (herpes simplex virus) 1&2 Assay in the fourth quarter of 2015. Instruments Luminex LX 100/200: The Luminex LX 100/200 Systems are compact analyzers that integrate fluidics, optics and digital signal processing to perform up to 100 assays simultaneously in a single tube or well of a microtiter plate using only a small amount of sample. FLEXMAP 3D: The FLEXMAP 3D system is intended for use as a general laboratory instrument in markets, including life science research and diagnostics. This device can simultaneously measure up to 500 analytes from a single sample. Like the company’s Luminex LX 100/200 Systems, the FLEXMAP 3D system combines semiconductor lasers with digital signal processors and microcontrollers and these systems perform multi-analyte profiles under the control of a Windows-based personal computer and its proprietary software. MAGPIX: The MAGPIX system is a multiplexing analyzer capable of performing qualitative and quantitative analysis of proteins and nucleic acids in various sample matrices. This system can perform up to 50 tests in a single reaction volume, reducing sample input, reagents and labor while improving productivity. MAGPIX is based on a detection mechanism that uses light emitting diodes and a charge-coupled device (CCD) imaging system, rather than the lasers and detection mechanisms used in its flow cytometry-based instruments. ARIES: The ARIES system is a sample to answer real-time PCR platform. The ARIES system uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and Batch testing. The ARIES system can run both IVD assays and MultiCode analyte specific reagents simultaneously with a common Universal Assay Protocol. Consumables MicroPlex Microspheres: The company
(LMNX:Consolidated Issue Listed on NASDAQ Global Select )
12212 Technology Boulevard
Austin, TX 78727
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for LMNX.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.